The peptide regulatory landscape in 2026 is in active flux. After the FDA placed 19 popular peptides in Category 2 in late 2023, HHS Secretary RFK Jr. announced in February 2026 that FDA Peptide Reclassification 2026 Amanecia Health New: An FDA decision to place 19 peptides on the unsafe list was supported by numerous documented safety concerns, former officials said. Even though demand for peptide therapies has exploded since then, Not all peptides are restricted. Here's the breakdown you actually need. The FDA's Category 2 classification affects specific compounded peptides BPC 157, TB 500, CJC 1295 Ipamorelin, AOD 9604, Epithalon, Selank, Semax. Others like Sermorelin